Uric acid transporter inhibitors for gout
نویسندگان
چکیده
Gout is a common inflammatory arthritis that is caused by chronically-elevated serum uric acid (sUA) levels (hyperuricemia). In humans, sUA levels are predominantly controlled by a variety of transporters that mediate the elimination of uric acid through the kidneys and intestines, a process that is altered in most gout patients. In this review, we highlight our current understanding of uric acid handling in healthy individuals and gout patients, therapies for gout that target uric acid transporters, and the mechanism of other therapies that alter sUA levels through interactions with uric acid transporters.
منابع مشابه
NEW DRUG APPROVALS Zurampic for Hyperuricemia Associated With Gout
NEW DRUG APPROVALS Zurampic for Hyperuricemia Associated With Gout The FDA has approved lesinurad (Zurampic, AstraZeneca) to treat high levels of uric acid in the blood (hyper uricemia) associated with gout. Lesinurad is to be used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the pro duction of uric acid in the body. Lesinu rad helps the kidney ex...
متن کاملErratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
BACKGROUND Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1 inhibitors probenecid and benzbromarone are used as gout therapies; however, their use is limited by drug-drug interactions and off-target ...
متن کاملMechanism of high affinity inhibition of the human urate transporter URAT1
Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1. We exploited affinity differences between the human and rat transporters to map inhibitor binding sites in URAT1. Human-rat transporter chimeras revealed that human URAT1 serine-35, phenylalanine-365 and isoleucine-481 are necessary and sufficient to provide up to a 100-fold...
متن کاملRecent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics
Although dietary, genetic, or disease-related excesses in urate production may contribute to hyperuricemia, impaired renal excretion of uric acid is the dominant cause of hyperuricemia in the majority of patients with gout. The aims of this review are to highlight exciting and clinically pertinent advances in our understanding of how uric acid is reabsorbed by the kidney under the regulation of...
متن کاملHomology Modeling and Molecular Docking of URAT1 with Chemotherapeutic Agents for Hyperuricemia and Gout
Uric acid transporter 1 (URAT1), a protein involved in uric acid reabsorption, has been linked to pathogenesis of hyperuricemia and gout. Hence, targeting this protein is essential for improving drug design and preventing adverse interactions. The present study was aimed to build URAT1 3D structures by homology modeling and to examine chemotherapeutic drugs binding to URAT1 and the interactions...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2017